Neoplasia/BPH

	Evolving Treatments and Resistance Mechanisms in Prostate Cancer Therapeutics. ACS Pharmacol Transl Sci Sai Rishma Reddy GSV, Kumar A, Sharma NK, Samanta K, Pramanik D, Karampudi NBR, Kar P. PMID: 41988377 [PubMed]
	A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma. Front Immunol Palacka P, Málek T, Makovník M, Felediová R, Rychlý B, Kolníková G. PMID: 41988182 [PubMed - indexed for MEDLINE]
	Predictors of pathological upstaging to pT3a after nephrectomy for cT1 renal tumors: a systematic review and meta-analysis. Front Oncol Ye Y, Bai J, Ye Y, Lin B, Zou G, Huang J, Zheng C, Qiu Q, Zhong D, Lin J, Chen J, Cai W, Zhu S. PMID: 41988130 [PubMed]
	Primary healthcare-friendly prostate cancer prediction model using routine clinical parameters: a multicenter study. Front Oncol Chen M, Li T, Yang S, Zhou Y, Lin H, Lan J, Zhang X, Yang X, Zhou J, Lyu G. PMID: 41988122 [PubMed]
	Micro-ultrasound tissue echogenicity predicts prostate cancer grade. BJUI Compass Corona AE, Luca D, Sohrabi KK, Grunden K, Chen W, Sarmadian PJ, Walsh KJ, Kwan L, Miao Q, Sung K, Brisbane WG. PMID: 41987882 [PubMed]
	Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial. Clin Transl Med Liu Z, Chen B, Dai T, Jiang S, Luo H, Liao H, Yu D, Chen Z, Zhang D, Li Z, Zhang Z, Bai H, Liu F, Lin J, Wang Y, Feng P, Wei Q. PMID: 41987598 [PubMed - indexed for MEDLINE]
	Kidney disease and determinants of health as correlates to primary bone cancer: a cross-sectional US population-based study. BMC Nephrol Shouman M, Jaffa AA, Jaffa MA. PMID: 41987130 [PubMed - as supplied by publisher]
	Lymphedema and self-reported swelling among Danish survivors of prostate cancer - prevalence, clinical associations and functional implications. Support Care Cancer Levinsen AKG, Ammitzbøll G, Kjaer TK, Borre M, Larsen SB, Dalton SO. PMID: 41986761 [PubMed - indexed for MEDLINE]
	Predictive value of early PSMA upregulation for the response to enzalutamideâ€‰Â±â€‰(177)Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nat Cancer Emmett L, Swiha M, Papa N, Subramaniam S, Crumbaker M, Joshua AM, Nguyen A, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Pathmanandavel S, Hope T, Ayati N, Hofman MS, Sandhu S, Niu C, Martin AJ, Thomas H, Stockler MR, Davis ID, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. PMID: 41986500 [PubMed - as supplied by publisher]
	Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer. Urol Clin North Am Penukonda S, Hyams E, Pareek G, Santopietro A, Carneiro B. PMID: 41986019 [PubMed - indexed for MEDLINE]
	Treatments on the Horizon for Men with Advanced Prostate Cancer. Urol Clin North Am Ehrlich MI, Gejman RS, Bernstein E, Stein MN. PMID: 41986027 [PubMed - indexed for MEDLINE]
	Systemic Treatments of Castration-Resistant Prostate Cancer. Urol Clin North Am Desai AN, Fleyshman M, Lall N, Saraiya B. PMID: 41986026 [PubMed - indexed for MEDLINE]
	Recent Advances in Understanding the Biology of Castration-Resistant Prostate Cancer. Urol Clin North Am Lluís D, Cheng W, Piulats JM, Heras L, Aytes Á, Kruithof de Julio M. PMID: 41986025 [PubMed - indexed for MEDLINE]
	Radiotherapy in Men with De Novo Metastatic Prostate Cancer. Urol Clin North Am Messing I, Rao YJ, Goyal S. PMID: 41986024 [PubMed - indexed for MEDLINE]
	Cytoreductive Radical Prostatectomy in Men with De Novo Metastatic Prostate Cancer. Urol Clin North Am Ragam R, Chua KJ, Wei J, Aron M. PMID: 41986023 [PubMed - indexed for MEDLINE]
	Systemic Treatments in Men with De Novo Metastatic Prostate Cancer. Urol Clin North Am Lim DH, Zhang A, Kim IY. PMID: 41986022 [PubMed - indexed for MEDLINE]
	Managing Prostate Cancer Biochemical Recurrence after Definitive Local Therapy. Urol Clin North Am Winograd J, Suzman E, Wang S, Hu JC. PMID: 41986021 [PubMed - indexed for MEDLINE]
	Managing Clinical N1 Prostate Cancer. Urol Clin North Am Imam S, Yuh B. PMID: 41986020 [PubMed - indexed for MEDLINE]
	Modern Radiotherapy for High-Risk and Very-High-Risk Prostate Adenocarcinoma. Urol Clin North Am Shen J, An Y. PMID: 41986018 [PubMed - indexed for MEDLINE]
	Role of Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer: Should It be Done? Urol Clin North Am Elkun Y, Gupta R, De Almeida Luz M, Tewari AK. PMID: 41986017 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 187104

Page 1 of 9356



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy